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1. INTRODUCTION {#hex12575-sec-0005}
===============

Peptic ulcer is defined as an ulcer occurring in a region that touches gastric acid and pepsin, and usually refers to a gastric or duodenal ulcer. Although peptic ulcers have a very low mortality rate, they can have complications such as haemorrhage and perforation if not treated in time. They can cause significant physical pain to patients and increase financial and service burdens. One report found that the lifetime prevalence of peptic ulcer disease in the general population has been estimated to be about 5%‐10%, and incidence 0.1%‐0.3% per year.[1](#hex12575-bib-0001){ref-type="ref"}, [2](#hex12575-bib-0002){ref-type="ref"}, [3](#hex12575-bib-0003){ref-type="ref"} Although peptic ulcers are a benign, non‐fatal disease, they do result in lost productivity and associated economic loss.

Distress caused by peptic ulcers includes psychological, social and behavioural problems, which may interfere with a patient\'s ability to fully participate in their health care, and manage their illness and its consequences. The widely accepted bio‐psycho‐social medical model includes quality of life (QoL), which is the general well‐being of individuals and societies, outlining negative and positive features of life. It is understood to be a multidomain concept with physical, psychological and social components, however which is insufficient to assess the patients treatment‐related effects. Besides, some of the symptoms associated with treatment, such as nausea and vomiting, are frequently underreported by clinicians, even when data are prospectively collected within clinical trials. Only relying on the results of clinical examination and the judgement of experts without patients' perception could indirectly lead to misdiagnosis and medical accidents because of the different opinions between doctors and patients. Developing a patient‐centred measure tool can enhance the self‐efficacy of patients to recognize and report symptoms of deteriorating conditions, improve patient 's self‐efficacy, identify and report the deterioration of symptoms and able to actively contribute to the management of chronic diseases.[4](#hex12575-bib-0004){ref-type="ref"}, [5](#hex12575-bib-0005){ref-type="ref"} Patient‐reported outcomes (PROs) have been demonstrated to be a valid, reliable, feasible and precise approach to evaluate clinical research and enables symptoms that are missed by clinicians to be detected.

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR), the European Regulatory Issues on Quality of Life Assessment Group (ERIQA), the United States Food and Drug Administration (FDA)[6](#hex12575-bib-0006){ref-type="ref"} and the International Society for Quality of Life Studies (ISQOL) recommend that clinical efficacy evaluation should include outcomes provided by patients and proxy respondents. Patient‐reported outcomes (PROs) are a central aspect.[7](#hex12575-bib-0007){ref-type="ref"} A PRO is a measurement of any aspect of a patient\'s health status that originates directly from the patient (i.e, without the interpretation of the patient\'s responses by a physician or other person).[8](#hex12575-bib-0008){ref-type="ref"} A PRO can directly reflect the influence of disease in a patient, help in the treatment of that patient and help to establish good communication between the patient and medical staff in determining treatment efficiency. In addition, a PRO can help to explain clinical outcomes and treatment decisions made.

In recent years, many effective and reliable measures for the digestive system have been developed internationally and applied in practice. Commonly used measures include the Sickness Impact Profile (SIP),[9](#hex12575-bib-0009){ref-type="ref"} the Nottingham Health Profile (NHP)[10](#hex12575-bib-0010){ref-type="ref"} and the Quality of Well‐being (QWB).[11](#hex12575-bib-0011){ref-type="ref"} The Medical Outcomes Study Short Form‐36 (SF‐36) is the most well‐known and widely accepted measure.[12](#hex12575-bib-0012){ref-type="ref"} Specific health‐related QoL (HRQoL) measures commonly used include the Quality of life in peptic diseases (QPD) questionnaire,[13](#hex12575-bib-0013){ref-type="ref"} Peptic ulcer diseases questionnaire (PUDQ), Ulcer esophagitis subject symptom (UESS), Quality of life in duodenal ulcer patients (QLDUP).[14](#hex12575-bib-0014){ref-type="ref"}

Many studies have been performed on the demographic and clinical characters and health‐related quality of life in the disease‐specific patients based on all those measures. However, these scales all have a specific focus, and cannot fully reflect the actual situation of patients with peptic ulcers. Therefore, in this study, we aimed to develop a PRO measure for peptic ulcer patients (PU‐PROM) that (I) was developed from the perspective of patients and could be widely applied in evaluations of clinical curative effect; (II) is established across four domains (physical, psychological, social and treatment) to comprehensively reflect health status and quality of life in patients with peptic ulcers; (III) can be specifically used to report the clinical outcomes of patients with peptic ulcers; (IV) comprised items that were easy to understand and answer (responses on 5‐point Likert scale).

2. METHODS {#hex12575-sec-0006}
==========

2.1. Ethics statement {#hex12575-sec-0007}
---------------------

The study protocol and the PU‐PROM were reviewed and approved by the Medical Ethics Committee of Shanxi Medical University.

2.2. Study population and design {#hex12575-sec-0008}
--------------------------------

Based on the principles of the United States FDA, we performed a comprehensive review of the literature and related measures, conducted semi‐structured interviews with patients with peptic ulcers and consulted relevant experts. We extracted and integrated information from these sources to form a theoretical framework and an initial item pool. The interview participants were 10 patients with peptic ulcers with a consistent disease distribution by sex and age, including six men and four women aged 40.01±9.81 years. The six experts consulted included three chief peptic ulcer physicians, one psychologist, one sociologist and one ethics expert. Based on the patient interviews and expert consultation, we debugged and modified the expressions of items in the initial item pool.

For the first item screening stage, 200 participants were sampled from eight hospitals at different levels in Shanxi Province, China. This included 150 patients with peptic ulcers and 50 controls. Completed questionnaires were examined using classical test theory (CTT) and item response theory (IRT), to select and adjust the item pool, and a preliminary measure was developed. This was followed by a formal investigation, with 550 patients with peptic ulcers and 150 controls, using the same method to reduce the items and form the final measure. Finally, the reliability, validity, differential item functioning (DIF) and feasibility of the measure were verified.

2.3. Development of the PU‐PROM {#hex12575-sec-0009}
-------------------------------

The PU‐PROM was developed in three phases: (i) conceptual framework construction and initial item generation; (ii) formation of the final measure by two item selection process based on the CTT and IRT; and (iii) validation of the PU‐PROM. Phase 1 involved a qualitative analysis, whereas the other two phases used quantitative analyses. A flow chart of this developmental process is shown in Figure [1](#hex12575-fig-0001){ref-type="fig"}.

![Developmental process flow chart](HEX-20-1350-g001){#hex12575-fig-0001}

### 2.3.1. Step 1: Item generation {#hex12575-sec-0010}

#### Identifying the conceptual framework and initial item content {#hex12575-sec-0011}

We searched for related literature of PRO measures to build the conceptual framework of PU‐PROM. The theoretical framework was established including four domains and 12 subdomains: physiology (subdomains: physical symptoms, independence and physical status); psychology (subdomains: work stress, anxiety, depression and fear); society (subdomains: social support and social adaptation); and treatment (subdomains: compliance, degree of satisfaction and availability). Then, the patients were interviewed to understand the main symptoms, the influence of the psychological and social, and the evaluation of treatment satisfaction; all of the information were collected and collated to form the item pool. Next, the item pool was revised based on discussions with the six experts and 10 patients. They put forward items that ambiguous in words and difficult to understand should be deleted, and some items should be added. Subsequently, an initial version of the measure was developed, using four domains, 11 subdomains (independence was excluded from the physiology domain) and 64 items.

### 2.3.2. Step 2: Item selection {#hex12575-sec-0012}

#### Sampling survey {#hex12575-sec-0013}

We selected a sample comprising 150 peptic ulcer patients and 50 controls from the eight participating hospitals in Shanxi Province. Patients who were diagnosed with a definite peptic ulcer, who were fully competent and who volunteered to participate were included in this study. Patients were excluded if they had deficiencies in language or cognitive abilities that meant they could not understand or complete the questionnaire; mental illness; or disturbance of consciousness. The controls did not have peptic ulcers, malignant tumours or mental illness, and had a similar age distribution to the patient group.

In the process of evaluating the patients' completed questionnaires, 20 were invalid and 130 were valid, giving a valid response rate of 87%. The valid response rate for the controls was 100%.

Reponses to all items were on a 5‐point Likert scale, where recorded as 0‐4 points. The 5‐point scale form was most commonly chosen as the easiest to complete, and item omission was least frequent with this form. Nagata suggests that the 5‐point scale is most useful for measuring health status.[15](#hex12575-bib-0015){ref-type="ref"} The measure contained positive items and negative items. Positive items were scored as the original score plus one and negative items were scored as five minus the original score. Missing data were tested by Little\'s Missing Completely at Random test, and the *P*‐value was \<.001.[16](#hex12575-bib-0016){ref-type="ref"} Items considered as missing at random were imputed based on the expectation‐maximization algorithm.[16](#hex12575-bib-0016){ref-type="ref"}

#### Statistical methods for item selection {#hex12575-sec-0014}

The item reduction for the preliminary measure was based on CTT and IRT. CTT includes discrete trend, factor analysis, correlation coefficients, Cronbach\'s α if an item is deleted, retest reliability and differentiation degree analysis. These methods were combined with specialized knowledge to assess the items. Items selected at by least five methods were kept, although this meant that other methods might have suggested that the item be removed. The final version of the preliminary measure comprised four domains, 11 subdomains and 54 items (10 items were deleted).

#### CTT {#hex12575-sec-0015}

##### Discrete trend {#hex12575-sec-0016}

The scores of all items (derived from the 5‐point Likert scale) could be regarded as similar to normal processing. A low discrete trend indicates people inclined to select the same answer, and the item has poor evaluation ability. We used the standard deviation (SD) to measure the discrete degree of items. Items with a low SD (\<1.0) were deleted.

##### Factor analysis {#hex12575-sec-0017}

We used principal component factor analysis, with the largest orthogonal rotation according to the eigenvalue and the variance contribution rate of an item. The value for the Kaiser‐Meyer‐Olkin measure of sampling adequacy was \>0.5. Items with low factor loading (\<0.4) and cross‐measurement with more than one other item were deleted.

##### Correlation coefficient {#hex12575-sec-0018}

Items were filtered by representativeness and independence, which showed the item satisfied the purpose of the PROM. An item that showed a low correlation coefficient (\<0.6) in relation to its subdomain was deleted.

##### Cronbach\'s alpha if item was deleted (CAID) {#hex12575-sec-0019}

The method used internal consistency to choose items and ensure homogeneity.[17](#hex12575-bib-0017){ref-type="ref"} The internal consistency of items was evaluated by calculating the CITC and CAID values (Cronbach\'s α), when the CITC value was more than 0.45, which showed the item has highly contribution to the measured construct. The CAID values determined which item has highly contribution to the reliability of the PROM. Whether the Cronbach\'s α coefficient showing a big increment after an item was removed indicated that item was influential for internal consistency and it should be deleted.

##### Retest reliability {#hex12575-sec-0020}

Retest reliability reflects stability and consistency across time. We selected 4 days as the retest interval and calculated the correlation coefficient of the item score across two surveys. Items with low correlation coefficients (\<0.6) were deleted.

##### Differentiation degree analysis {#hex12575-sec-0021}

Whether the item could not make a distinction between different objects that should be deleted. We compared each item score for the patient and control groups by performing independent two‐sample *t*‐tests (α=0.05). Items with no statistical difference were deleted.

#### IRT {#hex12575-sec-0022}

Item response theory is a nonlinear model used to select items and test construction. It establishes a functional relationship between a participants' reaction to the item and their ability. This relationship is reflected by an item characteristic curve (ICC). Items were assessed using Multilog 7.03 with a grade response model. Each item\'s parameters of discrimination (α) and difficulty (b) were estimated. In general, items with a discrimination value of \<0.4 should be deleted. Difficulty was divided into four grades (b1, b2, b3 and b4) ranging from −3 to 3. Items outside this range should be considered for deletion.

#### Second sampling survey {#hex12575-sec-0023}

To verify the measure, we recruited 550 patients and 150 controls from the same eight hospitals, but only 492 and 124, respectively, were available to participate in the study. The response rate met the requirements, and the number of participants satisfied Nunnally\'s proposal.[18](#hex12575-bib-0018){ref-type="ref"} We used the same methods as used for the preliminary measure to revise the items.

Classical test theory and item response theory were used for item reselection. Combined with professional knowledge, we used at least five methods to evaluate the items. Three item evaluation methods were discarded. The results indicated that all 54 items should be kept to form the final measure.

### 2.3.3. Step 3: Validation of the measure {#hex12575-sec-0024}

Finally, we using the data obtained from these 492 patients as well as 124 control participants to examine the reliability, validity, DIF and feasibility of the final measure.

#### Reliability {#hex12575-sec-0025}

Reliability refers to the consistency of the test results; the higher the measured value of homogeneity, the better the reliability.[19](#hex12575-bib-0019){ref-type="ref"} Cronbach\'s α coefficient and retest reliability are frequently used in reliability analyses. Cronbach\'s α coefficient is the most commonly used method. In this study, we calculated every subdomain\'s Cronbach\'s α coefficient. And generally, the α value should be more than 0.7. Retest reliability reflects the stability and homogeneity across time. And it is generally believed that the correlation coefficient should be more than 0.6.

#### Validity {#hex12575-sec-0026}

Validity analysis evaluates the validity of a questionnaire. This involves content validity, construction validity and discriminant validity. Content validity reflects the degree to which the selected items represent the expected content.[19](#hex12575-bib-0019){ref-type="ref"} Construction validity (or structure validity) examines whether the multi‐index measurement is a professionally ideal structure, testing the structure from clinical and common sense perspectives. A measure with good construction validity can obtain true latent trait of subjects during measurement. We used confirmatory factor analysis (CFA) to build a measurement model between the item and the subdomain that included the item. We used LISREL 8.70 software (Scientific Software International. Inc. 7383 North Lincoln Avenue, Suite 100 Lincolnwood, IL 60712‐1704) for the CFA.[20](#hex12575-bib-0020){ref-type="ref"} In addition, the evaluation of the fit effect of the model for every domain was also used multiple indexes, commonly fit index including: GFI, RMR, NFI, NNFI, IFI, CFI.[21](#hex12575-bib-0021){ref-type="ref"} Discriminant validity reflects small changes across different populations and different times. It can reflect the different trait of selected subjects. Discriminant validity was assessed by comparing the mean score of the patients and the controls to ensure whether each subdomain correctly distinguish the two types of people. Generally, we used a simple independent two‐sample *t*‐test to compare patients and controls. When the *P*‐value was \<.05, we considered the difference to be statistically significant, and the measure to have a good degree of differentiation.

#### DIF {#hex12575-sec-0027}

As a test result has personal, social and political ramifications, it should be reliable, valid and fair.[22](#hex12575-bib-0022){ref-type="ref"} To investigate whether a test item is fair among members of different subgroups such as males and females and majority groups and minority groups, a plethora of research on DIF has been conducted.[23](#hex12575-bib-0023){ref-type="ref"}, [24](#hex12575-bib-0024){ref-type="ref"} This verified the quality of the questionnaire and ensured the validity and fairness of the measure. DIF is generally divided into two types of uniform DIF and non‐uniform DIF. Uniform DIF is present when an item differs across groups in item difficulty parameters, while non‐uniform DIF is present when an item differs across members of different subgroups in item discrimination parameters.[25](#hex12575-bib-0025){ref-type="ref"} The MACS model identifies non‐uniform DIF and uniform DIF using unidimensional multistage scoring. If there is no DIF in the items of all subdomains, we further confirmed it by the comparison of nested models. Comparing the chi‐square difference between the "measurement equivalence model" and the "baseline model," if the difference was not significant, the items of the subdomains did not exist DIF; if there is DIF in the items of all subdomains, we need to compare the chi‐square difference between the "measurement equivalence model" and the "partial measurement equivalence model"; if the difference has statistical significance, indicating that the items exist DIF.

#### Feasibility {#hex12575-sec-0028}

Feasibility is used to reflect the degree of acceptability of a measure. This is characterized by acceptance rate, response rate and completion times. In general, the recovery rate of the questionnaires should more than 85%, and the response rate also should more than 85%. In addition, time for each person answered should be controlled within 15 minutes.

2.4. Statistical software {#hex12575-sec-0029}
-------------------------

Data analyses were performed with [spss]{.smallcaps}, version 16.0 (SPSS for Windows, Version 16.0. Chicago, SPSS Inc.), Multilog 7.03 and LISREL 8.70.

3. RESULTS {#hex12575-sec-0030}
==========

3.1. Participant characteristics {#hex12575-sec-0031}
--------------------------------

In the first survey with the preliminary measure, 130 patients with peptic ulcers aged 41.25±5.97 years and 50 controls aged 40.00±5.49 years completed the measure. In the formal survey, 492 patients aged 41.84±8.81 years and 124 controls aged 41.35±8.35 years completed the measure. Tables [1](#hex12575-tbl-0001){ref-type="table-wrap"} and [2](#hex12575-tbl-0002){ref-type="table-wrap"} present the participants' characteristics, and in the first item pool reduction phase, and the revaluation and validation phase, respectively.

###### 

Baseline data for participants in sample survey

  Variables         Peptic ulcer   Control       *t*/χ^2^   *P*
  ----------------- -------------- ------------- ---------- ------
  Age (years)       41.25±5.97     40.00±5.49    1.290      .199
  Gender                                                    
  Male              65             31            2.089      .148
  Female            65             19                       
  Height (cm)       165.90±4.97    165.52±4.70   0.466      .642
  Weight (kg)       64.08±7.84     63.64±8.03    0.478      .634
  Drinking                                                  
  Never             37             16            0.616      .959
  Quit              62             23                       
  Occasional        29             10                       
  Always            2              1                        
  Smoking                                                   
  Never             14             8             2.121      .548
  Quit              47             19                       
  10 branches/d     44             12                       
  10 branches/d\~   25             11                       

John Wiley & Sons, Ltd

###### 

Baseline data for participants in formal survey

  Variables         Peptic Ulcer   Control       *t*/χ^2^   *P*
  ----------------- -------------- ------------- ---------- ------
  Age (years)       41.84±8.81     41.35±8.35    0.555      .579
  Gender                                                    
  Male              283            82            3.040      .081
  Female            209            42                       
  Height (cm)       164.87±2.26    165.53±5.82   −1.230     .219
  Weight (kg)       64.96±7.29     66.37±6.96    −1.948     .052
  Drinking                                                  
  Never             142            31            1.041      .791
  Quit              228            58                       
  Occasional        110            32                       
  Always            12             3                        
  Smoking                                                   
  Never             112            33            1.577      .665
  Quit              228            50                       
  \<10 branches/d   116            31                       
  10 branches/d\~   36             10                       

John Wiley & Sons, Ltd

3.2. Item generation {#hex12575-sec-0032}
--------------------

Through a large number of literature, expert consultation and patient interviews, we conducted a conceptual framework consisted of four domains, 12 subdomains and a pool of 77 items. Next, we selected items based on interviewing 10 patients with peptic ulcer and consulting six relevant experts to ensure that all the remaining items are easy to understand and related to the topic. So, one domain and 18 items describing atypical symptoms and overlap with each other were deleted, and five items were added. Therefore, there are four domains, 11 subdomains and 64 items were generated for the initial peptic ulcer PRO measure. The items are described in Additional file 1: Appendix [1](#hex12575-app-0001){ref-type="app"}.

3.3. Item selection {#hex12575-sec-0033}
-------------------

The two‐step item selection process was based on CTT and IRT. This iterative process resulted in a final version comprised four domains, 11 subdomains and 54 items. For the first phase, statistical results for the items are given in Table [3](#hex12575-tbl-0003){ref-type="table-wrap"}. As we can see, 10 items (PHD15, PHD16, PSD14, PSD15, PSD16, PSD20, SOD4, SOD8, SOD9, THA8) were deleted based on the criteria described in the Methods. To ensure the reliability and validity of each item, we used the same methods to re‐select items and considered their practical significance based on the experts' opinions for each item. All items remained after this process. Figure [2](#hex12575-fig-0002){ref-type="fig"} shows the matrix plot of the ICCs for each item. Ideally, the first ICC curve should decrease monotonously, the last curve should increase monotonously and the other curves follow a normal distribution. The closer the ICC distribution is to the ideal state, the more information it contains, and vice versa. As seen in Figure [2](#hex12575-fig-0002){ref-type="fig"}, most items were satisfactory. Therefore, the preliminary measure comprised four domains, 11 subdomains and 54 items (Appendix [2](#hex12575-app-0002){ref-type="app"}).

###### 

Item selection outcome based on CTT and IRT

  Subdomain   Item    IRT     SD      *t*     Factor Loading   CAID    CC      Retest Reliability   Outcome                           
  ----------- ------- ------- ------- ------- ---------------- ------- ------- -------------------- --------- ------- ------- ------- ---
  SOM         PHD1    2.17    −0.78   0.27    0.64             1.84    1.172   0.001                0.756     0.902   0.634   0.769   √
  PHD2        2.97    −0.38   0.20    0.57    1.30             1.285   0.001   0.858                0.895     0.777   0.843   √       
  PHD3        2.08    −0.78   −0.33   0.14    1.02             1.206   0.001   0.793                0.897     0.748   0.810   √       
  PHD4        2.07    −1.21   −0.63   0.08    0.80             1.110   0.001   0.775                0.898     0.717   0.664   √       
  PHD5        2.37    −0.87   −0.42   0.01    0.75             1.151   0.001   0.780                0.897     0.737   0.737   √       
  PHD6        1.39    −1.88   −1.16   −0.26   1.21             1.022   0.001   0.654                0.900     0.661   0.780   √       
  PHD7        1.45    −1.66   −0.75   0.10    1.85             1.016   0.007   0.663                0.900     0.678   0.691   √       
  PHD8        2.18    −1.39   −0.46   0.16    1.23             1.022   0.001   0.425                0.901     0.642   0.725   √       
  PHD9        3.12    −0.61   −0.50   0.26    1.10             1.038   0.001   0.546                0.897     0.739   0.702   √       
  PHD10       2.61    −0.95   −0.42   0.27    1.19             1.018   0.330   0.544                0.903     0.598   0.784   √       
  PHD11       2.18    −0.93   −0.67   −0.15   1.08             1.019   0.004   0.610                0.904     0.586   0.772   √       
  PHD12       1.75    −4.25   −0.96   −0.72   0.23             0.882   0.001   0.734                0.904     0.565   0.715   √       
  PHD13       1.75    −0.57   0.36    0.86    1.96             1.260   0.039   0.603                0.903     0.640   0.656   √       
  PHD14       1.70    −4.46   −0.66   0.07    0.77             1.074   0.001   0.651                0.900     0.679   0.766   √       
  PHD15       0.83    −7.42   −1.73   −0.99   1.62             0.960   0.008   0.405                0.797     0.625   0.741   ×       
  PHD16       1.30    −5.54   −1.33   −0.18   1.46             0.909   0.014   0.417                0.794     0.620   0.784   ×       
  PHY         PHD17   2.37    −1.11   −0.34   0.10             1.17    1.073   0.103                0.815     0.693   0.855   0.760   √
  PHD18       3.29    −0.89   −0.35   0.03    0.99             1.009   0.003   0.794                0.718     0.809   0.828   √       
  PHD19       0.87    −3.21   −2.35   −1.22   1.04             1.004   0.023   0.811                0.741     0.765   0.775   √       
  WOR         PSD1    1.92    −0.52   0.03    0.57             1.40    1.354   0.001                0.678     0.833   0.881   0.822   √
  PSD2        2.17    −1.30   −0.04   0.42    1.17             1.171   0.030   0.790                0.802     0.876   0.828   √       
  PSD3        1.59    −1.41   −0.35   0.16    1.19             1.211   0.001   0.792                0.770     0.896   0.751   √       
  ANX         PSD4    4.43    −0.65   −0.09   0.26             0.95    1.102   0.001                0.682     0.912   0.782   0.717   √
  PSD5        3.89    −0.68   −0.21   0.30    1.18             1.026   0.001   0.771                0.904     0.833   0.729   √       
  PSD6        4.28    −0.64   −0.22   0.41    0.93             1.062   0.004   0.849                0.901     0.857   0.662   √       
  PSD7        4.04    −2.56   −0.20   0.59    1.02             1.003   0.001   0.848                0.906     0.820   0.719   √       
  PSD8        4.04    −0.67   −0.08   0.37    1.04             1.090   0.001   0.861                0.901     0.859   0.713   √       
  PSD9        2.87    −1.20   −0.42   0.29    1.13             0.980   0.005   0.727                0.911     0.775   0.751   √       
  PSD10       3.99    −0.50   −0.37   0.04    0.96             1.029   0.002   0.782                0.907     0.812   0.698   √       
  DEP         PSD11   0.16    −8.32   −1.11   5.87             16.96   1.194   0.001                0.717     0.645   0.781   0.709   √
  PSD12       0.55    −9.25   −1.57   0.97    3.62             1.015   0.001   0.765                0.661     0.734   0.750   √       
  PSD13       0.20    −9.58   −2.45   3.21    10.47            1.207   0.001   0.786                0.587     0.831   0.756   √       
  PSD14       0.28    −9.30   −0.05   4.52    13.33            0.938   0.001   0.428                0.743     0.602   0.700   ×       
  PSD15       1.14    −5.97   −0.91   0.48    1.93             0.987   0.046   0.594                0.775     0.655   0.736   ×       
  PSD16       2.24    −1.88   −0.45   0.09    1.22             0.984   0.001   0.440                0.773     0.662   0.740   ×       
  FEA         PSD17   2.70    −0.90   −0.60   −0.21            0.65    1.018   0.004                0.684     0.743   0.757   0.635   √
  PSD18       1.77    3.90    −4.44   −0.75   1.05             1.027   0.087   0.726                0.765     0.695   0.711   √       
  PSD19       2.45    −1.14   −0.38   −0.32   0.82             1.058   0.001   0.726                0.726     0.806   0.816   √       
  PSD20       1.74    −2.02   −1.09   −0.64   0.86             0.890   0.422   0.550                0.780     0.618   0.851   ×       
  SOC         SOD1    2.53    −0.98   −0.08   0.28             1.40    1.084   0.001                0.833     0.735   0.791   0.827   √
  SOD2        3.04    −0.71   −0.31   0.09    1.20             1.032   0.001   0.792                0.738     0.780   0.822   √       
  SOD3        2.25    −1.33   −0.39   0.15    1.08             1.060   0.001   0.773                0.763     0.734   0.874   √       
  SOD4        1.80    −2.33   −0.86   −0.64   0.56             0.940   0.264   0.405                0.788     0.648   0.874   ×       
  SOD5        1.57    −1.41   −1.15   −0.80   0.82             1.015   0.050   0.554                0.753     0.748   0.893   √       
  SUP         SOD6    0.68    −5.46   −1.96   −0.16            2.43    1.027   0.001                0.508     0.799   0.512   0.824   √
  SOD7        0.28    −7.28   −1.09   1.25    7.27             1.228   0.001   0.696                0.736     0.791   0.776   √       
  SOD8        0.54    −9.14   0.12    1.51    5.90             0.992   0.022   0.701                0.783     0.587   0.728   ×       
  SOD9        0.54    −8.46   −1.31   0.57    5.31             0.939   0.330   0.779                0.801     0.479   0.766   ×       
  SOD10       0.44    −8.62   −3.33   −1.42   2.73             1.033   0.202   0.807                0.747     0.744   0.650   √       
  SOD11       0.67    −5.10   −2.01   −1.75   1.85             1.033   0.122   0.896                0.732     0.803   0.850   √       
  SOD12       0.56    −3.91   −2.84   −1.14   1.83             1.175   0.019   0.780                0.755     0.727   0.830   √       
  COM         THA1    0.98    −6.64   −2.25   −0.25            2.16    0.811   0.027                0.796     0.811   0.805   0.717   √
              THA2    0.66    −3.60   −1.88   −0.36            3.99    1.021   0.057                0.879     0.783   0.860   0.789   √
              THA3    0.39    −6.45   −3.81   −0.62            4.60    1.054   0.010                0.743     0.815   0.824   0.838   √
              THA4    0.71    6.34    −8.80   −1.54            1.56    1.026   0.116                0.722     0.808   0.829   0.700   √
  AVA         THA5    0.48    −4.97   −3.29   0.18             4.46    1.021   0.067                0.797     0.687   0.813   0.751   √
  THA6        0.77    −2.88   −2.25   −1.10   2.41             1.035   0.001   0.753                0.705     0.794   0.924   √       
  THA7        0.47    −5.48   −3.02   −1.52   3.81             1.052   0.134   0.790                0.680     0.823   0.776   √       
  THA8        0.38    −7.09   −5.74   −3.76   3.28             0.944   0.378   0.569                0.795     0.652   0.819   ×       
  SAT         THA9    1.01    5.35    −6.70   −1.30            1.95    1.005   0.030                0.732     0.801   0.745   0.860   √
  THA10       0.82    6.24    −7.88   −2.20   2.45             1.002   0.009   0.856                0.759     0.847   0.700   √       
  THA11       0.89    −2.74   −1.21   0.24    3.23             1.004   0.163   0.81                 0.773     0.815   0.729   √       
  THA12       1.02    −1.72   −1.64   −0.56   2.72             1.040   0.001   0.775                0.793     0.768   0.802   √       
  THA13       0.38    −4.82   −1.56   −0.39   5.63             1.249   0.001   0.657                0.841     0.706   0.826   √       

"CC" is the abbreviation of Correlation Coefficient. × represents the item considered to be deleted, and √ considered to be kept.
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3.4. Validation of the measure {#hex12575-sec-0034}
------------------------------

The reliability, validity, DIF and feasibility of the 54 items were assessed, and the results are presented in the followed.

3.5. Reliability {#hex12575-sec-0035}
----------------

Cronbach\'s α coefficient is an important indicator for the reliability. In general, its value should more than 0.70. For our PU‐PROM, the Cronbach\'s α of each subdomain was more than 0.800 for the measure and ranged from 0.817 to 0.907 for the four domains, indicating the measure was reliable (Table [4](#hex12575-tbl-0004){ref-type="table-wrap"}). In addition, we conducted a repeated survey of 50 patients, and the correlation coefficients of each item were \>0.60, which showed the measure has high retest reliability.

###### 

Cronbach\'s α coefficient of four domains and total measure

  Domain          Subdomain   Cronbach\'s α coefficient
  --------------- ----------- ---------------------------
  Physical        SOM         0.897
  PHY             0.854       
  Psychological   WOR         0.907
  ANX             0.884       
  DEP             0.884       
  FEA             0.905       
  Social          SOC         0.901
  SUP             0.817       
  Treatment       COM         0.844
  AVA             0.881       
  SAT             0.871       
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3.6. Validity {#hex12575-sec-0036}
-------------

The measure was also found to have good content validity as it allows direct communication with patients[26](#hex12575-bib-0026){ref-type="ref"}, [27](#hex12575-bib-0027){ref-type="ref"} and they thought the PU‐PROM was easy to understand and response. In the process of the item building and modifying phase, experts also agreed the measure was reasonable and comprehensive in content. We conducted CFA for the 54 items to investigate the factor structure of the measure. We also found that the indices of fit (GFI, RMR, NFI, NNFI, CFI, IFI) met the expected structure. On the whole, GFI, NFI, NNFI, CFI and IFI are all more than 0.90, and RMR is \<0.09. The results are shown in Tables [5](#hex12575-tbl-0005){ref-type="table-wrap"} and [6](#hex12575-tbl-0006){ref-type="table-wrap"}. The measure was able to distinguish between patients with peptic ulcers and controls. Our analysis of the different average scores using the independent two‐sample *t*‐test showed that all *P*‐values were \<.05, indicating the measure had a good degree of differentiation (Table [7](#hex12575-tbl-0007){ref-type="table-wrap"}). As controls did not receive treatment and could not answer items in the treatment domain, no comparison was made for the SAT (satisfaction) subdomain.

###### 

Goodness‐of‐fit statistics of CFA for PU‐PROM

          GFI    RMR     NFI    NNFI   CFI    IFI
  ------- ------ ------- ------ ------ ------ ------
  PHD     0.81   0.100   0.88   0.88   0.90   0.90
  PSD     0.93   0.056   0.95   0.96   0.97   0.97
  SOD     0.98   0.038   0.98   0.98   0.99   0.99
  THA     0.94   0.045   0.95   0.95   0.96   0.96
  Total   0.80   0.072   0.86   0.91   0.92   0.92
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###### 

Maximum likelihood estimation of CFA for PU‐PROM

  Domain   Subdomain   Item   Factor loading   SE      *t*     *R* ^2^   Error variance
  -------- ----------- ------ ---------------- ------- ------- --------- ----------------
  PHD      SOM         PHD1   0.69             0.05    14.83   0.39      0.73
  PHD2     0.90        0.05   17.24            0.50    0.83              
  PHD3     0.76        0.06   13.61            0.34    1.11              
  PHD4     0.76        0.05   14.30            0.37    0.98              
  PHD5     0.91        0.05   17.03            0.49    0.88              
  PHD6     0.85        0.05   16.05            0.44    0.90              
  PHD7     0.67        0.05   14.21            0.37    0.77              
  PHD8     0.64        0.05   13.83            0.35    0.75              
  PHD9     0.76        0.05   15.37            0.42    0.80              
  PHD10    0.64        0.05   13.47            0.34    0.82              
  PHD11    0.63        0.05   13.42            0.33    0.79              
  PHD12    0.68        0.05   13.70            0.35    0.87              
  PHD13    0.71        0.05   13.84            0.35    0.93              
  PHD14    0.81        0.06   13.96            0.36    1.18              
  PHY      PHD15       1.04   0.04             23.11   0.81    0.25      
  PHD16    0.80        0.04   17.88            0.54    0.54              
  PHD17    0.89        0.04   20.00            0.65    0.43              
  PSD      WOR         PSD1   1.03             0.05    22.38   0.71      0.44
  PSD2     1.16        0.05   25.16            0.83    0.28              
  PSD3     1.23        0.05   24.04            0.78    0.43              
  ANX      PSD4        1.02   0.05             19.96   0.61    0.67      
  PSD5     1.08        0.05   21.70            0.68    0.55              
  PSD6     0.96        0.04   22.98            0.73    0.34              
  PSD7     0.95        0.05   20.76            0.64    0.50              
  PSD8     0.84        0.05   17.19            0.49    0.73              
  PSD9     0.68        0.05   13.20            0.32    0.96              
  PSD10    0.60        0.05   12.12            0.28    0.94              
  DEP      PSD11       0.95   0.05             20.94   0.66    0.46      
  PSD12    0.89        0.04   21.72            0.70    0.34              
  PSD13    1.09        0.05   23.76            0.79    0.31              
  FEA      PSD14       1.00   0.04             24.81   0.81    0.23      
  PSD15    0.96        0.04   25.10            0.82    0.20              
  PSD16    1.07        0.05   22.24            0.70    0.49              
  SOD      SOC         SOD1   0.94             0.04    20.92   0.65      0.47
  SOD2     0.99        0.04   23.75            0.77    0.30              
  SOD3     0.96        0.04   23.13            0.74    0.32              
  SOD4     0.99        0.05   20.84            0.65    0.54              
  SUP      SOD5        0.65   0.05             13.44   0.35    0.79      
  SOD6     0.95        0.05   18.70            0.59    0.64              
  SOD7     0.83        0.04   19.94            0.64    0.39              
  SOD8     0.55        0.05   10.57            0.23    0.98              
           SOD9        0.93   0.05             20.05   0.65    0.47      
  THA      COM         THA1   0.67             0.04    16.14   0.46      0.53
  THA2     0.65        0.05   13.73            0.36    0.75              
  THA3     0.98        0.04   22.33            0.75    0.32              
  THA4     0.97        0.04   21.80            0.72    0.36              
  AVA      THA5        0.82   0.04             20.33   0.64    0.38      
  THA6     0.93        0.04   23.73            0.80    0.22              
  THA7     0.89        0.04   21.71            0.70    0.33              
  SAT      THA8        0.63   0.05             13.96   0.36    0.71      
  THA9     0.89        0.04   23.34            0.76    0.25              
  THA10    0.87        0.04   22.71            0.73    0.28              
  THA11    0.74        0.04   18.37            0.55    0.46              
  THA12    0.75        0.04   18.32            0.54    0.48              
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###### 

Scores comparison between peptic ulcer patients and controls

  Subdomain   Peptic Ulcer   Controls     *t*/*t′*   *P*
  ----------- -------------- ------------ ---------- --------
  SOM         47.07±11.02    61.50±2.08   −27.197    \<.001
  PHY         11.93±2.96     13.31±0.92   −8.781     \<.001
  WOR         9.77±3.59      12.12±1.22   −12.046    \<.001
  ANX         23.88±6.49     30.26±1.47   −19.869    \<.001
  DEP         9.96±3.12      12.66±1.07   −15.866    \<.001
  FEA         11.57±3.17     13.36±0.96   −10.763    \<.001
  SOC         14.26±4.08     16.93±1.31   −12.219    \<.001
  SUP         19.03±4.33     21.39±1.42   −10.074    \<.001
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3.7. DIF {#hex12575-sec-0037}
--------

This study used a mean and covariance structure (MACS) model based on sex for the DIF analysis, through which we examined whether there were differences between men and women. We performed DIF analysis for the 11 subdomains by sex (Table [8](#hex12575-tbl-0008){ref-type="table-wrap"}). As the subdomains including: physical status (PHY), work stress (WOR), depression (DEP), fear (FEA) and availability (AVA) all contained only three items, their degree of freedom was 0, which cannot be well fitted the "baseline model," so in the study, items contained in these subdomains did not exist DIF. For the subdomain of "social adaptation (SUP)," the result suggested that there are differences in model fitting, items exist DIF, but modification index (MI) prompted the item difficulty parameters and discrimination parameters are cross gender equal. The results showed there is not significant DIF. Other subdomains of DIF analysis results are shown that the items of the PU‐PROM do not exist DIF.

###### 

Transgender DIF nested model results

                                                                          χ^2^       *df*                           GFI         RMR      RMSEA    NFI     NNFI    CFI     IFI      Δχ^2^   Δ*df*
  --------------------------------------- ------------------------------- ---------- ------------------------------ ----------- -------- -------- ------- ------- ------- -------- ------- -------
  SOM                                     Measurement equivalence model   1032.561   195                            0.806       0.123    0.132    0.869   0.901   0.894   0.894            
  Baseline model                          1001.553                        154        0.805                          0.108       0.150    0.873    0.872   0.892   0.892   31.008   41      
                                          MI1=2.662, *P*\>.05/14                     MI2=2.211, *P*\>.05/13         *P*\>.05                                                               
  PHY                                     Measurement equivalence model   14.423     8                              0.972       0.143    0.0572   0.976   0.991   0.989   0.988            
  WOR                                     Measurement equivalence model   10.238     8                              0.985       0.0595   0.0338   0.988   0.998   0.997   0.997            
  ANX                                     Measurement equivalence model   170.847    48                             0.910       0.105    0.102    0.941   0.962   0.957   0.956            
  Baseline model                          154.355                         10         0.924                          0.0703      0.136    0.946    0.933   0.955   0.956   16.492   38      
                                          MI1=4.288, *P*\>.05/7                      MI2=1.082, *P*\>.05/6          *P*\>.05                                                               
  DEP                                     Measurement equivalence model   12.247     8                              0.985       0.106    0.0465   0.984   0.995   0.994   0.994            
  FEA                                     Measurement equivalence model   9.313      8                              0.980       0.0678   0.0259   0.989   0.999   0.998   0.998            
  SOC                                     Measurement equivalence model   21.438     15                             0.970       0.0525   0.0419   0.985   0.997   0.996   0.996            
  Baseline model                          17.676                          4          0.973                          0.0303      0.118    0.988    0.973   0.991   0.991   3.762    11      
                                          MI1=0.743, *P*\>.05/4                      MI2=1.321, *P*\>.05/3          *P*\>.05                                                               
  SUP                                     Measurement equivalence model   53.386     24                             0.958       0.0869   0.0707   0.954   0.978   0.974   0.974            
  Baseline model                          28.690                          10         0.975                          0.0501      0.0873   0.975    0.966   0.983   0.983   24.696   14      
                                          MI1=2.099, *P*\>.05/5                      MI2=2.216 (SOD6), *P*\>.05/4   *P* \<.05                                                              
  Partial measurement equivalence model   53.412                          23         0.958                          0.0870      0.0735   0.954    0.977   0.973   0.973   −0.026   1       
                                          MI3=2.134, *P*\>.05/4                      MI4=2.215, *P*\>.05/4          *P*\>.05                                                               
  COM                                     Measurement equivalence model   100.327    15                             0.892       0.0957   0.152    0.897   0.928   0.910   0.910            
  Baseline model                          91.545                          4          0.899                          0.0741      0.299    0.909    0.736   0.912   0.913   8.782    11      
                                          MI1=0.780, *P*\>.05/4                      MI2=0.997, *P*\>.05/3          *P*\>.05                                                               
  AVA                                     Measurement equivalence model   8.934      8                              0.983       0.0628   0.0218   0.987   0.999   0.998   0.998            
  SAT                                     Measurement equivalence model   50.964     24                             0.954       0.154    0.0677   0.968   0.985   0.982   0.982            
  Baseline model                          36.804                          10         0.971                          0.0371      0.105    0.977    0.965   0.983   0.983   14.16    14      
                                          MI1=0.417, *P*\>.05/5                      MI2=1.411, *P*\>.05/4          *P*\>.05                                                               

Modification index 1 (MI1) represents the largest fixed index associated with the intercept, and MI2 is associated with the load of the factors. MI3, MI4 represent the above interpretation after the item "SOD6" being removed, respectively.
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3.8. Feasibility {#hex12575-sec-0038}
----------------

The acceptance rate and completion rate of the measure were beyond 85%, and the average completion time was within 15 minutes, indicating that the measure was feasible.

Therefore, the final PU‐PROM is comprised of four domains, 11 subdomains and 54 items (Appendix [3](#hex12575-app-0003){ref-type="app"}) ,and the theoretical framework is shown in the Table [9](#hex12575-tbl-0009){ref-type="table-wrap"}.

###### 

Construction frame of final PU‐PROM

  Domain                       Subdomain                     Item
  ---------------------------- ----------------------------- ------------------------------------------------------------
  Physical domain (PHD)        Physical symptoms (SOM)       1−, 2−, 3−, 4−, 5−, 6−, 7−, 8−, 9−, 10−, 11−, 12−, 13, 14−
  Physical status (PHY)        15−, 16−, 17−                 
  Psychological domain (PSD)   Work stress (WOR)             1−, 2−, 3−
  Anxiety (ANX)                4−, 5−, 6−, 7−, 8−, 9−, 10−   
  Depression (DEP)             11−, 12, 13                   
  Fear (FEA)                   14−, 15−, 16−                 
  Social domain (SOD)          Social support (SOC)          1−, 2−, 3−, 4−
  Social adaptation (SUP)      5, 6, 7, 8, 9                 
  Treatment domain (THA)       Compliance (COM)              1, 2, 3, 4
  Availability (AVA)           5, 6, 7                       
  Satisfaction (SAT)           8−, 9, 10, 11, 12             

"−"means negative item, others means positive item.
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4. DISCUSSION {#hex12575-sec-0039}
=============

Peptic ulcers have various causes and mainly occur in the stomach and duodenum mucosa. A peptic ulcer is a chronic disease characterized by high incidence, low mortality, spontaneous remission and periodical paroxysms. The main peptic ulcer complications are haemorrhage and perforation. The disease leads to a decrease in productivity and brings significant loss to society, and the treatment cost contributes to social and economic burdens. Therefore, a PRO measure for peptic ulcers may improve patients' QoL and can be used to evaluate clinical curative effect.

Patients are increasingly involved in evaluations of health‐care quality.[28](#hex12575-bib-0028){ref-type="ref"}, [29](#hex12575-bib-0029){ref-type="ref"}, [30](#hex12575-bib-0030){ref-type="ref"} Internationally, many HRQoL measures have been developed and applied in chronic diseases of the digestive system. However, existing measures have some deficiencies. For example, the NHP focuses on a more serious disability level and is not sensitive to relatively mild condition changes; the SIP has wide coverage, but is very long; and the SF‐36 is widely used, but does not identify specific areas of the disease. The QPD is restricted to functional dyspepsia patients. The UESS involves fewer items and uses a 100 mm visual record to show the degree of symptom severity; higher scores indicate more serious symptoms. The PUDQ only involves three aspects of ulcers (pain, mood and social function) and does not accurately reflect the status of the disease. The QLDUP only reflects QOL in duodenal ulcer patients. In addition, at present, these questionnaires are mainly focused on physiology, psychology and society, and are limited.

Our peptic ulcer PRO measure (PU‐PROM) has improved on the disadvantages of the above tools. This is a specific measure for peptic ulcers. It has a high correlation with the disease, and the results can reflect the actual life‐experience of patients. Our PU‐PROM also includes a new and significant concept of a treatment domain, which is comprehensive, and does not only consider the HRQoL index in the traditional sense. By measuring the patient\'s satisfaction, compliance and side‐effects of drugs, our measure also provides a basis for clinical treatment, new drug research and development, and clinical review.

In developing the measure, we used cognitive investigation to form the conceptual framework, CTT and IRT to select items, and CFA to validate items. The United States FDA has emphasized the importance of clinical outcomes and provided guidance for the establishment of PRO measures.[31](#hex12575-bib-0031){ref-type="ref"} This study was based on FDA guidance, and our methods of investigation strictly followed the established PRO measure production process. We used expert and patient opinions and suggestions to build an initial measure. A sample investigation that combined CTT and IRT was used to select items. After a large‐scale formal investigation, we evaluated the reliability, validity, DIF and feasibility of the measure, finalizing a PRO measure for patients with peptic ulcers that included four domains, 11 subdomains and 54 items.

A standard operating procedure was used to: generate appropriate items and domains; ensure the instrument was comprehensive relative to its intended measurement concept, population and context of use; and ensure patient understanding of the instrument (i.e, instructions, items and response options).[32](#hex12575-bib-0032){ref-type="ref"}

In contrast to previous assessments of measures, we directed attention to the items rather than the structure validity of the measure. Items for the PU‐PROM were based on a review of the literature and other related questionnaires, face‐to‐face interviews with patients and discussions with expert professionals. The content validity index further strengthened the content validity of our preliminary measure, as in the development process, we selected items by this index. The role of content validity index in the process of preparation and evaluation cannot be ignored, and can meet the quality requirements of the measure before implementation.

In the development stage, we used CTT and IRT to select the items, striving for items that had strong representativeness, independence and high sensitivity. CTT is easier to understand and is more commonly used than IRT. However, it neglects the estimation of the respondent\'s ability, and the reliability of the results is inadequate. Compared with the CTT, IRT has some advantages including: the estimate of the respondent\'s ability is independent of the item; the difficulty parameter of the items and respondent\'s ability is unified; parameter estimation of items is independent; and the accuracy of the estimator of the respondent\'s ability can be estimated. Use of the IRT enriched the representativeness, independence, internal consistency, sensitivity, fairness and importance of the items. However, the results of the measure should also be considered in combination with clinical knowledge and the patient\'s illness and psychological state, to ensure the quality of the measure.

Differential item functioning is a research hotspot in the field of psychology and education measurement. DIF is more commonly used in the detection of fairness and effectiveness of examination questions. This study introduced DIF into the process of developing a clinical measure and broadened the application scope of DIF. The influence of DIF on the content of the measure provided a new method for item selection and content evaluation, and improved the quality of the developed measure.

The PU‐PROM we developed fills a gap in clinical outcome measurement for patients with peptic ulcers, and addresses the deficiencies in existing tools. It will also provide valuable data for new drug development for peptic ulcers, because PROs are increasingly included as key primary or secondary end points in clinical studies to support drug development.[33](#hex12575-bib-0033){ref-type="ref"}

However, there were some limitations in this study that should be resolved and improved in the future research. First, there were two clinical investigations during the development of the measure, and the results might have been affected by the investigation environment to produce bias. Respondents and investigators might have also affected the results of the study. Second, we did not use criterion validity to measure the PRO measure. As the content of the measure is various, and considering the patients' physical and psychological states, we did not choose a well‐established measure as a criterion to test consistency. Third, the PRO measure scores were calculated using a 5‐point Likert scale, but there is no clear and suitable method to evaluate the overall QoL. Forth, the sample populations may not fully represent the entire population of patients with peptic ulcer. Our participants were from only the Shanxi province in northern China. Therefore, future research should explore the reliability and validity of the PU‐PROM with a nationwide sample. The PU‐PROM was administrated to native‐Chinese speaking individuals. Therefore, further work is needed to conduct cross‐cultural adaptation in different countries. Fifth, we performed DIF analysis for the 11 subdomains by sex, which showed sex had no influence on peptic ulcer, but we did not analyse age. We should consider the effect of age in the next application and development of the PU‐PROM. In addition, there are no standard quantitative indicators to support clinical decision making for the corresponding disease. Finally, we did not consider the demands of DIF analysis in the design phase, which made the numbers of items in some subdomains too small, meaning that in the process of DIF analysis, a "baseline model" could not be implemented. Additional studies should further expand the scope as well as the number of participants. We should also compare our PU‐PROM with a criterion measure and assess the measure in terms of the range, reliability, validity and applicability.

5. CONCLUSIONS {#hex12575-sec-0040}
==============

Our study makes important contributions to the treatment and outcomes of patients with peptic ulcers and develops a specific measurement instrument for this group. We found strong evidence for the reliability and validity of our PU‐PROM. However, we do not consider that our PU‐PROM is able to replace other related questionnaires. Therefore, we need to further improve the measure to ensure it suitable for a wider range of people. We could also extend the measure for other uses such as patients' health conditions, clinical effects evaluation, new drug development, health service deployment and clinical research.
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ItemItemPHD1. Do you have epigastric pain?PSD14. Are you optimistic about the future?PHD2. Does the pain change with food?PSD15. Are you worried about bringing harm to yourself or a loved one?PHD3. Is the pain getting worse when you are hungry?PSD16. Are you feeling fine about everything? Nothing bad will happen, right?PHD4. Is the pain getting worse after meals?PSD17. Do you feel frustrated and hopeless about your illness?PHD5. Do you have epigastric pain during the night?PSD18. Do you feel the illness is a burden of your family?PHD6. Is the epigastric pain regular?PSD19. I don\'t want to talk about my illness to other people.PHD7. Do you have abdominal distension?PSD20. I am not interested in social activities any more.PHD8. Do you have heartburn in your stomach?SOD1. Is your job affected by your illness?PHD9. Do you have acid regurgitation?SOD2. Are your hobbies affected by your illness (such as playing chess, dancing)?PHD10. Do you have eructation?SOD3. Does your illness prevent you from taking family responsibilities?PHD11. Do you feel nauseated?SOD4. Does your illness estrange you from your relatives, neighbours and friends?PHD12. Do you have hematemesis?SOD5. Does your illness prevent you from participating the social and family activities?PHD13. Is your bowel movement OK?SOD6. My family is concerned about my illness.PHD14. Have you noticed any changes in the colour of your faeces, for example, are they getting darker?SOD7. My relatives, neighbours and friends all care about my illness.PHD15. Do you feel dizzy?SOD8. My relatives, neighbours and friends all give me material help and support.PHD16. Do you feel general weakness?SOD9. My relatives, neighbours and friends all give me spiritual help and support.PHD17. Do you feel fatigue?SOD10. My family gives me material help and support.PHD18. Do you have loss of appetite?SOD11. My family gives me spiritual help and support.PHD19. Have you lost any weight?SOD12. The family often reminds me of medication.PSD1. Do you do repetitive work?THA1. Take my medicine as instructed.PSD2. Is your work trivial, complicated and big workload?THA2. I follow my doctor\'s instruction and get rid of my bad habits.PSD3. Does your job have requirement on hours and speed?THA3. I follow my doctor\'s instruction and do regular follow‐ups.PSD4. Are you stressed or nervous than usual?THA4. All of the checks and tests about my illness are necessary.PSD5. Are you more irritable?THA5. Treatment is effective for my illness..PSD6. Do you get angry more easily than usual?THA6. My mood improved after treatment.PSD7. Do you feel unhappy and depressed?THA7. I have physical improvement after treatment.PSD8. Are you worried about the epigastric pain?THA8. My life confidence increased after treatment.PSD9. Is your sleep affected by the pain?THA9. Are you worried about the side‐effects of your medicine?PSD10. Are you bothered by your indigestion?THA10. The doctors are friendly to me.PSD11. Do you feel it difficult to concentrate to do one thing?THA11. Are you satisfied with the medical services?PSD12. Do you have no difficulty in doing your daily activities?THA12. Are you satisfied with the costs of medical care?PSD13. Are you still interested in the activities you love to do?THA13. Are you satisfied with current treatment?
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ItemItemPHD1. Do you have epigastric pain?PSD11. Do you feel it difficult to concentrate to do one thing?PHD2. Does the pain change with food?PSD12. Do you have difficulty in doing your daily activities?PHD3. Is the pain getting worse when you are hungry?PSD13. Are you still interested in the activities you love to do?PHD4. Is the pain getting worse after meals?PSD14. Do you feel frustrated and hopeless about your illness?PHD5. Do you have epigastric pain during the night?PSD15. Do you feel the illness is a burden of your family?PHD6. Is the epigastric pain regular?PSD16. I don\'t want to talk about my illness to other people.PHD7. Do you have abdominal distension?SOD1. Is your job affected by your illness?PHD8. Do you have heartburn in your stomach?SOD2. Are your hobbies affected by your illness (such as playing chess, dancing)?PHD9. Do you have acid regurgitation?SOD3. Does your illness prevent you from taking family responsibilities?PHD10. Do you have eructation?SOD4. Does your illness estrange you from participating the social and family activities?PHD11. Do you feel nauseated?SOD5. My family is concerned about my illness.PHD12. Do you have hematemesis?SOD6. My relatives, neighbours and friends all care about my illness.PHD13. Is your bowel movement OK?SOD7. My family gives me material help and support.PHD14. Have you noticed any changes in the colour of your faeces, for example, are they getting darker?SOD8. My family gives me spiritual help and support.PHD15. Do you feel fatigue?SOD9. The family often reminds me of medication.PHD16. Do you have loss of appetite?THA1. Take my medicine as instructed.PHD17. Have you lost any weight?THA2. I follow my doctor\'s instruction and get rid of my bad habits.PSD1. Do you do repetitive work?THA3. I follow my doctor\'s instruction and do regular follow‐ups.PSD2. Is your work trivial, complicated and big workload?THA4. All of the checks and tests about my illness are necessary.PSD3. Does your job have requirement on hours and speed?THA5. Treatment is effective for my illness.PSD4. Are you stressed or nervous than usual?THA6. My mood improved after treatment.PSD5. Are you more irritable?THA7. I have physical improvement after treatment.PSD6. Do you get angry more easily than usual?THA8. Are you worried about the side‐effects of your medicine?PSD7. Do you feel unhappy and depressed?THA9. The doctors are friendly to me.PSD8. Are you worried about the epigastric pain?THA10. Are you satisfied with the medical services?PSD9. Is your sleep affected by the pain?THA11. Are you satisfied with the costs of medical care?PSD10. Are you bothered by your indigestion?THA12. Are you satisfied with current treatment?
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NeverOccasionallyAbout half of the timeOftenAlmost everydayA. Physical domain1. I had epigastric pain012342. I felt the pain change with food012343. I thought the pain getting worse when I am hungry012344. I thought the pain getting worse after meals012345. I had epigastric pain during the night012346. I had epigastric pain regular012347. I had abdominal distension012348. I had heartburn in my stomach012349. I had acid regurgitation0123410. I had eructation0123411. I felt nausea0123412. I had hematemesis0123413. I thought my bowel movement is OK0123414. My face looked dark and dull0123415. I felt fatigue0123416. I felt loss of appetite0123417. I was losing weight01234NeverOccasionallyAbout half of the timeOftenAlmost everydayB. Psychological domain1. Doing repetitive work012342. The work is trivial, complicated and big workload012343. Work has requirement on hours and speed012344. I felt stressed or nervous than usual012345. I felt more irritable012346. I got angry more easily than usual012347. I felt unhappy and depressed012348. I was worried about the epigastric pain012349. My sleep was affected by the pain0123410. I was bothered by indigestion0123411. I felt it difficult to concentrate to do one thing0123412. I have difficulty in doing my daily activities0123413. I felt interested in the activities I love to do0123414. I felt frustrated and hopeless about my illness0123415. I thought the illness is a burden of my family0123416. I didn\'t want to talk about my illness to other people01234NeverOccasionallyAbout half of the timeOftenAlmost everydayC. Social domain1. My job affected by the illness012342. My hobbies affected by the illness012343. My illness prevent me from taking family responsibilities012344. My illness estrange me from participating the social and family activities012345. My family is concerned about my illness012346. My relatives, neighbours and friends all care about my illness012347. My family gives me material help and support012348. My family gives me spiritual help and support012349. The family often reminds me of medication01234NeverOccasionallyAbout half of the timeOftenAlmost everydayD. Treatment domain1. Take medicine as instructed012342. Follow doctor\'s instruction and get rid of bad habits012343. Follow doctor\'s instruction and do regular follow‐ups012344. I thought the checks and tests are necessary012345. I thought my treatment is effective for my illness012346. My mood improved after treatment012347. I have physical improvement after treatment012348. I was worried about the side‐effects of my medicine01234**Very dissatisfactionDissatisfactionGeneral satisfactionSatisfactionVery satisfaction**9. The doctors are friendly to me0123410. I was satisfied with the medical services0123411. I was satisfied with the costs of medical care0123412. I was satisfied with current treatment01234
